Fabulous #UCSFDOM R3 talk by ⁦Rohini Kopparam⁩ on care of the pregnant patient! I learned so much. #UCSFproud #WIC ⁦UCSF Cardiology⁩ ⁦Cedars-Sinai⁩

Thanks for this important and groundbreaking work. And continuing to try to improve evidence requirements for FDA CDER approvals to protect patients.

Congrats on first RCT >10 yrs after ⁦⁦FDA/CDRH Industry⁩ approval. Should not be the last! It answers some questions, raises many more. No benefit in women. And would like to see longer term follow up, this trial started enrollment in 2013.⁩ statnews.com/2024/04/07/abi…

Grateful for the voices of Gregg Gonsalves & Cathy Collet on this STAT #STATSummit panel on U.S. FDA's role: 'Without robust confirmatory studies, Gonsalves feared the FDA was ceding its regulatory role in favor of a 'Yelp for drug development.'' statnews.com/2024/03/25/pat…

Physicians need more education on FDA drug and device regulation. Sanket Dhruva, Aaron Kesselheim, and Rita Redberg explain the results of their recent Health Affairs research and propose solutions MedPage Today Genevieve Friedman 
medpagetoday.com/opinion/second…

Our polar plunge, that is snow and ice in the water behind us. #WIC

In a national survey of 500 internists by Aaron Kesselheim Rita Redberg SanketDhruva, only 41% and 17% of respondents reported ≥ moderate understanding of FDA drug and device approval process. There is an opportunity to include regulation in medical school and residency curricula.…

Read more by authors Sanket Dhruva, Steven Woloshin, Aaron Kesselheim, Robin Ji, Zhigang Lu, Jonathan J Darrow, Rita Redberg: doi.org/10.1377/hlthaf…

I’m no fan of Rep. Elise Stefanik but I’m with her here. Claudine Gay’s hesitant, formulaic, and bizarrely evasive answers were deeply troubling to me and many of my colleagues, students, and friends:

Incredible reporting from @ProPublica w/insights from Madris Kinard and Rita Redberg. Rita Redberg raises concerns about delays in reporting and how they compromise patient safety. FDA Medical Devices

Great discussion of the importance of trial conduct and reporting free of bias and spin, to get right answers for patients. #CVCT2023

This test is as or more likely to be dangerous than beneficial , and could even increase cancer rates because of all the CT scans it leads to, which Medicare will also pay for. Not a good use of taxpayer dollars. Can drive up Medicare premiums.

Fabulous ⁦UCSF Cardiology⁩ #CPMC #AHA23 Journal Club. Hosted by the amazing ⁦ #AnnaBeyer . Great discussions and incredibly delicious (homemade) spread!

We need lower drug prices! There is no market operating in healthcare due to our patent system and other dysfunctional features. Prices often have no relation to value or R&D costs. statnews.com/2023/11/13/wei…

My favorite part of this great #AHA23 meeting is seeing friends. From the great cardiologists who helped start #WIC in the 90s to the newest leaders! ⁦Jennifer H. Mieres, MD , FACC, MASNC, FAHA⁩ ⁦Odayme Quesada, MD⁩ ⁦C Noel Bairey Merz⁩

Fascinating story of how to crowd source clinical research by the fabulous Sharonne Hayes MD in the #AHA23 Laennec lecture on #SCAD

Agree, she is a noteworthy mentor .

I find it remarkable and disappointing that one would do a trial of  taking people with CAD off their meds! I see no reason to ask this question and am surprised it would get IRB approval.  It is not a relevant clinical question.

Great piece in STAT on new research from Anika Kumar, Joseph Ross, Nisarg Patel, Vinay Rathi, Rita Redberg, and Sanket Dhruva. As the authors suggest, we need 'a more rigorous and inclusive approach to clinical research supporting FDA-authorized prescription digital therapeutics.”

What a great idea! John Mandrola, MD globalcyclingnetwork.com/lifestyle/fitn…